These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2090682)

  • 21. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.
    Fernández-Villar A; Sopeña B; Fernández-Villar J; Vázquez-Gallardo R; Ulloa F; Leiro V; Mosteiro M; Piñeiro L
    Int J Tuberc Lung Dis; 2004 Dec; 8(12):1499-505. PubMed ID: 15636498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin.
    Chan CH; Or KK; Cheung W; Woo J
    J Med; 1995; 26(1-2):43-52. PubMed ID: 7561530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
    Türktaş H; Unsal M; Tülek N; Orüç O
    Tuber Lung Dis; 1994 Feb; 75(1):58-60. PubMed ID: 8161767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced hepatotoxicity and tuberculosis in a hospital from the Argentinian northeast: cross-sectional study.
    Golemba AS; Ferreyra FG; Martearena RE; Achinelli FR; Rovai GB
    Medwave; 2015 May; 15(4):e6135. PubMed ID: 26035138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The impact of antituberculosis drugs upon liver function in patients with positive HBVM].
    Chen GQ
    Zhonghua Jie He He Hu Xi Za Zhi; 1989 Apr; 12(2):89-90, 126. PubMed ID: 2791129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-resistance of Mycobacterium tuberculosis in Patras, Greece.
    Trakada G; Tsiamita M; Spiropoulos K
    Monaldi Arch Chest Dis; 2004; 61(1):65-70. PubMed ID: 15366340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Risk factors of side effects of antituberculosis drugs].
    El Gharbi L; Baccar MA; Azzabi S; Aouina H; Kallel H; Daghfous R; Bouacha H
    Tunis Med; 2006 Aug; 84(8):487-91. PubMed ID: 17175689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore.
    Am Rev Respir Dis; 1986 Jul; 134(1):27-33. PubMed ID: 3524334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].
    Nagayama N; Shishido Y; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2004 May; 79(5):341-8. PubMed ID: 15211874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse reactions to first-line antituberculosis drugs.
    Forget EJ; Menzies D
    Expert Opin Drug Saf; 2006 Mar; 5(2):231-49. PubMed ID: 16503745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Toxicity of antitubercular agents for the liver].
    Dölle W
    Dtsch Med Wochenschr; 1973 Jan; 98(2):74. PubMed ID: 4683834
    [No Abstract]   [Full Text] [Related]  

  • 32. Correlates of hepatotoxicity and antituberculosis therapy in South Carolina.
    Dowda M; Sy FS; Dowda H; Pozsik CJ
    J S C Med Assoc; 1998 Jan; 94(1):16-20. PubMed ID: 9473867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Zierski M; Bek E
    Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
    [No Abstract]   [Full Text] [Related]  

  • 34. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
    Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicians' practices regarding management of antituberculosis drug-induced hepatotoxicity.
    Thongraung W; Lertphongpiroon W; Pungrassami P; Ratanajamit C
    Southeast Asian J Trop Med Public Health; 2012 May; 43(3):724-34. PubMed ID: 23077853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
    Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
    Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Surveillance and complications of antituberculosis chemotherapy].
    Duroux P
    Rev Prat; 1979 Jun; 29(33):2681-90. PubMed ID: 225779
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment.
    Sharifzadeh M; Rasoulinejad M; Valipour F; Nouraie M; Vaziri S
    Pharmacol Res; 2005 Apr; 51(4):353-8. PubMed ID: 15683749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.